Evidence map›Paper›PMID 34509324›Full record

ArticleVaccine2021

A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.

Xinglu Xu, Mark D Rodgers, Weihong Grace Guo

Abstract read
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinglu XuDepartment of Industrial and Systems Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA; State Key Laboratory of Coastal and Offshore Engineering, Dalian University of Technology, No.2 Linggong Road, Ganjingzi District, Dalian, Liaoning 116023, China.
Mark D RodgersDepartment of Supply Chain Management, Rutgers Business School, Rutgers, The State University of New Jersey, Piscataway, NJ 07102, USA.
Weihong Grace GuoDepartment of Industrial and Systems Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA. Electronic address: wg152@soe.rutgers.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An orderly and effective vaccination campaign is essential in combating the global COVID-19 pandemic. As one of the pioneers, the U.S. Center for Disease Control proposes a phased plan to promote the vaccination process. This plan starts with vaccinating the high-priority population in Phase 1, then turns to the remainder of the public in Phase 2, and ends with a scale-back network in Phase 3. The phased plan not only provides a sense of hope to impacted communities that this global pandemic can be defeated, but can serve as a template for other countries. To enhance this plan, this paper develops a generalizable framework for designing a hub-and-spoke vaccination dispensing network to achieve the goals in the Phase 2, which aims to expand the vaccination coverage for the general public. We introduce a new coverage index to measure the priority of different potential dispensing sites based on geo-data and develop an optimization model for network design. The hub-and-spoke network enhances the accessibility of the vaccines to various communities and helps to overcome the challenges related to ultra-cold storage facility shortage. A case study of Middlesex County in New Jersey is presented to demonstrate the application of the framework and provide insights for the Phase 2. Results from the baseline scenario show that increasing the driving time limit from 10 min to 25 min can improve the total coverage index from 40.8 to 55.9. Additionally, we explore how the changes of parameters impact the network design and discuss potential solutions for some special cases. When we allow 4 outreach nodes per hub, all potential 45 outreach points can be covered in the vaccination network within a 20-minute drive, and the total coverage index reaches its maximum value of 58.3.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansPandemicsSARS-CoV-2COVID-19 VaccinesVaccinesCOVID-19 pandemicNetwork designResource allocationVaccine distribution

Identifiers

PMID34509324
PMCPMC8384589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.